All relevant data are within the paper and are are publicly available in the NHANES website (<http://www.cdc.gov/nchs/nhanes/nh3data.htm>).

Introduction {#sec004}
============

In general, age-related body composition changes lead to an increase in visceral fat and a decrease in muscle mass and fat-free mass \[[@pone.0171707.ref001]--[@pone.0171707.ref002]\]. Sarcopenia, defined as a loss of muscle strength and mass, is correlated with slow gait speed, poor physical performance, decreased mobility, and increased mortality \[[@pone.0171707.ref002]\]. The prevalence of sarcopenia and sarcopenic obesity in adults in the United States (US) increases with age and is highly prevalent according to data obtained from the National Health and Nutrition Examination Survey (NHANES), 1999--2004 \[[@pone.0171707.ref003]\]. It has been well documented that individuals with a lower fat mass and higher muscle mass have better survival outcomes, quality of life and mental health \[[@pone.0171707.ref001]--[@pone.0171707.ref004]\].

Recently, several anthropometric parameters and measurements, including waist circumference, hip circumference, triceps skinfold (TSF) thickness, mid-arm circumference (MAC), and mid-arm muscle circumference (MAMC), have been widely used for nutritional identification and risk prediction. MAMC, which has been demonstrated to be highly related to lean muscle mass measured by dual energy X-ray absorptiometry, is a simple and dependable anthropometric measurement and has excellent reliability when performed by well-trained personnel \[[@pone.0171707.ref004]\]. Several studies have also demonstrated that a lower MAMC is associated with a higher mortality risk, poorer mental health and quality of life, and poorer functional performance \[[@pone.0171707.ref002]--[@pone.0171707.ref006]\]. However, the association between MAMC and all-cause mortality in the US general population has not been widely investigated. This prompted us to use NHANES III data to investigate whether MAMC is a risk factor for all-cause mortality among middle-aged and older adults in the US.

Materials and methods {#sec005}
=====================

Study population {#sec006}
----------------

We selected adults between 40 and 90 years of age in the NHANES III, which represents a multistage stratified investigation of the US population living in households during 1988--1994 \[[@pone.0171707.ref007]\]. Demographic information was collected through a structured home interview and accompanied by a series of physical examinations, nutrition assessments, which included anthropometric measurements and body-composition assessments, and blood sampling at a mobile examination center (MEC). The NHANES III study was executed in accordance with the Declaration of Helsinki and approved by the National Center for Health Statistics (NCHS) Institutional Review Board after obtaining the written informed consent of participants before starting the study.

Definition of the MAMC tertiles group {#sec007}
-------------------------------------

MAMC, as a marker of lean muscle mass, is calculated using the standard formula: MAMC = MAC--(3.14 x TSF thickness). The MAC was taken following standard procedures described by Lohman and colleagues and depending on the age of the participant \[[@pone.0171707.ref008]\]. Tertile-based analysis was used by dividing the MAMC into tertiles, with the participants in the lowest tertile as the reference group. All participants were initially divided into two groups based on gender, and then each group was divided into three subgroups (highest, middle and lowest, below and above cut-off level, respectively) depending on their MAMC level. The tertiles were as follows: T1 (18\<27.3), T2 (27.3\<29.6), T3 (29.6≤40.0) cm in the male group and T1 (15\<22.3), T2 (22.3\<24.6), T3 (24.6≤44.0) cm in the female group.

Follow-up data on all-cause mortality {#sec008}
-------------------------------------

The NHANES III also contained detailed mortality information and follow-up data from the time of study participation. The follow-up data on all-cause mortality were provided by the NCHS according to the probabilistic matching between National Death Index death certificate records and NHANES III participants. The complete follow-up data for all participants on all-cause mortality in the NHANES III study were from the date of exam until the date of death or censoring on December 31, 2006 \[[@pone.0171707.ref009]\].

Covariates {#sec009}
----------

The participants were interviewed to collect information concerning age, gender, race/ethnicity, body measurements, blood pressure, medical conditions (including self-reported physician-diagnosed hypertension, diabetes mellitus, malignancy, stroke, congestive heart failure, cognitive impairment, number of prescription medications taken), marital status and smoking status. After collecting three or four blood pressure (BP) measurements in the MEC and using a mercury sphygmomanometer during the home examinations, the average systolic and diastolic blood pressure readings were obtained. The presence of hypertension was defined by self-report of a physician's diagnosis or an average BP ≧140/90 mmHg. Diabetes mellitus was defined by a self-report of a physician's diagnosis or the presence of a random serum glucose level ≧200 mg/dL. Serum uric acid levels were measured via a Hitachi 737 automated multichannel chemistry analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN, USA). The serum biochemistry profile was measured by the Lipoprotein Analytical Laboratory at Johns Hopkins University, Baltimore, Maryland. Cognitive function was assessed from the result of simple reaction time test (SRTT: visual motor speed). Considering that treatments may affect the serum biochemistry and quantitative biomarkers, such as fasting glucose and lipid related measures, the hypertensive participants taking antihypertensive medications (N = 4103), hyperlipidemia treatments (N = 793), or diabetes mellitus treatments (N = 730) were excluded from the study. All measurements were completed with standardized methods and documented accuracy with respect to the Centers for Disease Control and Prevention (CDC) reference methods \[[@pone.0171707.ref009]\].

Data analysis {#sec010}
-------------

All statistical procedures and analyses were implemented using SPSS version 18 (SPSS, Inc., Chicago, IL). The analytic data were executed using the Complex Samples procedure to adjust for the clusters and strata of the complex sample design, incorporating sampling weights and preventing incorrect estimates of variance. Quantitative parameters were indicated as the values of the mean and standard deviation (SD). Demographic characteristics were compared using the Independent t-test or Wilcoxon Rank sum test for continuous variables and the Chi-square test for discrete variables. Two-sided p values of less than 0.05 were considered significant. A survival analysis was performed to examine the association of the MAMC with all-cause mortality. Kaplan-Meier survival curves were plotted to ascertain the relationship between MAMC in participants and subsequent mortality. Associations between MAMC tertiles and end points were evaluated in multivariable Cox proportional hazard models. The Cox proportional hazard assumption was met for the Cox model in the present study. Covariates adjustment was performed by an extended-model approach: Model 1 was not adjusted for other variables; Model 2 was further adjusted for age, race, sex, BMI and waist circumference; Model 3 = Model 2+ serum total cholesterol, serum HDL, serum glucose, C-reactive protein, serum uric acid, and serum total bilirubin; Model 4 = Model 3 + systolic blood pressure, smoking, type 2 diabetes mellitus and congestive heart failure; Model 5 = Model 4 + serum albumin, marital status, and number of prescription medications taken.

Results {#sec011}
=======

The study population in the NHANES III database consisted of the 6,769 adults who completed the MAMC measurement and laboratory examinations. Of the participants, 3,373 (49.8%) were male and 3,396 (50.2%) were female. The mean MAMC in the male group was 28.5±2.8 cm, and the mean age was 60.4±13.4 years. The mean MAMC in the female group was 23.8±3.0 cm, and the mean age was 60.5±13.8 years. The clinical characteristics of the male and female study population by MAMC tertiles are summarized in [Table 1](#pone.0171707.t001){ref-type="table"} and [Table 2](#pone.0171707.t002){ref-type="table"}. Male participants with higher MAMC tertiles tended to have a higher BMI and a larger waist circumference, higher diastolic blood pressure, higher serum total cholesterol level, lower serum HDL level, higher serum glucose level, lower C-reactive protein level, higher serum uric acid level and higher serum AST level than males in the lower MAMC tertile. Male participants in the higher MAMC tertile were less likely to be non-Hispanic white and to have malignancy or stroke than men in the lower MAMC tertile. Female participants in the higher MAMC tertile tended to have a higher BMI and a larger waist circumference, higher systolic and diastolic blood pressure, higher serum total cholesterol level, lower serum HDL level, higher serum glucose level, higher C-reactive protein level, higher serum uric acid level, and lower serum albumin level than women in the lower MAMC tertile. Female participants in the higher MAMC tertile were less likely to be non-Hispanic white and more likely to have type 2 diabetes mellitus and congestive heart failure than women in the lower MAMC tertile.

10.1371/journal.pone.0171707.t001

###### Characteristics of male individuals.

![](pone.0171707.t001){#pone.0171707.t001g}

  Characteristic                                          Tertiles of mid-arm muscle circumference (cm)                                             
  ------------------------------------------------------- ----------------------------------------------- ------------- ------------- ------------- ---------
  Continuous variables                                                                                                                              
      Mid-arm muscle circumference (cm), mean (SD)        25.6(1.6)                                       28.6(0.7)     31.7(1.6)     28.5(2.8)     \<0.001
      Age (years), mean (SD)                              66.4(13.6)                                      59.4(12.8)    54.9(11.1)    60.4(13.4)    \<0.001
      BMI (kg/m^2^), mean (SD)                            24.2(3.3)                                       26.9(3.2)     30.3(4.1)     27.0(4.3)     \<0.001
      Waist circumference (cm), mean (SD)                 93.0(10.3)                                      98.5(9.8)     105.4(11.3)   98.8(11.6)    \<0.001
      Systolic blood pressure (mmHg), mean (SD)           136.4(23.5)                                     133.0(21.1)   132.5(18.4)   134.0(21.3)   \<0.001
      Diastolic blood pressure (mmHg), mean (SD)          74.4(12.8)                                      76.9(11.7)    79.6(11.4)    76.9(12.2)    \<0.001
      Serum total cholesterol (mg/dL), mean (SD)          209.8(43.1)                                     213.2(41.9)   215.6(41.4)   212.8(42.2)   0.005
      HDL (mg/dL), mean (SD)                              49.1(15.7)                                      45.6(13.7)    43.8(13.4)    46.2(14.5)    \<0.001
      Serum glucose, mean (SD)                            105.1(36.2)                                     108.3(44.2)   109.0(41.7)   107.4(40.8)   0.046
      C-reactive protein, mean (SD)                       0.5(1.0)                                        0.5(0.8)      0.4(0.6)      0.5(0.8)      0.003
      Serum uric acid, mean (SD)                          5.8(1.4)                                        6.1(1.4)      6.4(1.3)      6.1(1.4)      \<0.001
      AST (U/L), mean (SD)                                23.0(14.0)                                      23.3(15.7)    24.6(12.9)    23.6(14.3)    0.019
      Serum total bilirubin, mean (SD)                    0.7(0.3)                                        0.7(0.3)      0.7(0.3)      0.7(0.3)      0.463
      Serum albumin (g/dL), mean (SD)                     4.1(0.4)                                        4.2(0.3)      4.2(0.3)      4.2(0.4)      \<0.001
  Categorical variables                                                                                                                             
      Non-Hispanic white, *n* (%)                         661(56.5)                                       575(51.1)     445(41.2)     1,681(49.8)   \<0.001
      Type 2 diabetes mellitus, *n* (%)                   107(9.2)                                        117(10.4)     125(11.6)     349(10.3)     0.121
      Malignancy, *n* (%)                                 72(6.2)                                         47(4.2)       28(2.6)       147(4.4)      0.001
      Stroke, *n* (%)                                     68(5.8)                                         48(4.3)       26(2.4)       142(4.2)      0.001
      Congestive heart failure, *n* (%)                   75(6.4)                                         56(5.0)       44(4.1)       175(5.2)      0.117
      Smoking, *n* (%)                                    330(28.2)                                       356(31.6)     316(29.3)     1002(29.7)    0.189
      Depression, *n* (%)                                 57(4.9)                                         51(4.5)       47(4.4)       155(4.6)      0.884
      Cognitive impairment, *N* (%)                       42(26.9)                                        51(19.9)      60(17.2)      153(20.1)     0.042
      Marital status, *N* (%)                                                                                                                       \<0.001
          Married, *N* (%)                                820(69.3)                                       845(75.1)     831(77.0)     2,486(73.7)   
          Widowed, *N* (%)                                22(1.9)                                         29(2.6)       17(1.6)       68(2.0)       
          Divorced, *N* (%)                               13(1.1)                                         28(2.5)       31(2.9)       72(2.1)       
          Separated, *N* (%)                              133(11.4)                                       60(5.3)       43(4.0)       236(7.0)      
          Never married, *N* (%)                          83(7.1)                                         89(7.9)       75(7.0)       247(7.3)      
          Living with partner, *N* (%)                    30(2.6)                                         23(2.0)       31(2.9)       84(2.5)       
      Number of prescription medications taken, *N* (%)                                                                                             0.153
          \<5                                             548(88.1)                                       491(90.6)     477(91.4)     1516(89.9)    
          \> = 5                                          74(11.9)                                        51(9.4)       45(8.6)       170(10.1)     

HDL, High-density lipoprotein; AST, aspartate aminotransferases; SD, standard deviation.

10.1371/journal.pone.0171707.t002

###### Characteristics of female individuals.

![](pone.0171707.t002){#pone.0171707.t002g}

  Characteristic                                          Tertiles of mid-arm muscle circumference (cm)                                             
  ------------------------------------------------------- ----------------------------------------------- ------------- ------------- ------------- ---------
  Continuous variables                                                                                                                              
      Mid-arm muscle circumference (cm), mean (SD)        20.9(1.1)                                       23.4(0.7)     27.0(2.4)     23.8(3.0)     \<0.001
      Age (years), mean (SD)                              61.0(14.7)                                      60.1(13.8)    60.3(12.8)    60.5(13.8)    0.245
      BMI (kg/m^2^), mean (SD)                            23.3(3.4)                                       27.1(3.7)     32.3(5.2)     27.6(5.6)     \<0.001
      Waist circumference (cm), mean (SD)                 83.6(9.4)                                       92.9(9.8)     103.9(11.4)   93.6(13.2)    \<0.001
      Systolic blood pressure (mmHg), mean (SD)           130.4(25.0)                                     132.6(23.6)   136.8(24.1)   133.3(24.4)   \<0.001
      Diastolic blood pressure (mmHg), mean (SD)          69.3(14.3)                                      71.4(13.3)    73.6(12.8)    71.4(13.6)    \<0.001
      Serum total cholesterol (mg/dL), mean (SD)          220.9(44.0)                                     225.0(45.8)   225.4(46.1)   223.8(45.4)   0.036
      HDL (mg/dL), mean (SD)                              59.7(17.5)                                      55.3(15.3)    51.9(14.9)    55.6(16.3)    \<0.001
      Serum glucose, mean (SD)                            100.0(40.9)                                     103.3(40.4)   116.2(53.5)   106.6(45.9)   \<0.001
      C-reactive protein, mean (SD)                       0.4(0.8)                                        0.5(0.9)      0.7(0.8)      0.5(0.9)      \<0.001
      Serum uric acid, mean (SD)                          4.6(1.3)                                        4.9(1.3)      5.3(1.5)      4.9(1.4)      \<0.001
      AST (U/L), mean (SD)                                20.5(9.2)                                       21.3(13.4)    21.0(10.3)    20.9(11.1)    0.194
      Serum total bilirubin, mean (SD)                    0.5(0.2)                                        0.50(0.2)     0.5(0.2)      0.5(0.2)      0.247
      Serum albumin (g/dL), mean (SD)                     4.1(0.3)                                        4.1(0.3)      4.0(0.3)      4.0(0.3)      \<0.001
  Categorical variables                                                                                                                             
      Non-Hispanic white, *n* (%)                         695(62.6)                                       608(53.2)     471(41.2)     1,774(52.2)   \<0.001
      Type 2 diabetes mellitus, *n* (%)                   77(6.9)                                         103(9.0)      215(18.8)     395(11.6)     \<0.001
      Malignancy, *n* (%)                                 79(7.1)                                         65(5.7)       63(5.5)       207(6.1)      0.291
      Stroke, *n* (%)                                     41(3.7)                                         34(3.0)       40(3.5)       115(3.4)      0.742
      Congestive heart failure, *n* (%)                   38(3.4)                                         33(2.9)       47(4.1)       118(3.5)      0.023
      Smoking, *n* (%)                                    8(0.7)                                          4(0.4)        8(0.7)        20(0.6)       0.432
      Depression, *n* (%)                                 98(8.8)                                         104(9.1)      87(7.6)       289(8.5)      0.553
      Cognitive impairment, *N* (%)                       66(27.0)                                        83(31.0)      105(40.9)     254(33.0)     0.003
      Marital status, *N* (%)                                                                                                                       0.018
          Married, *N* (%)                                579(52.1)                                       606(53.1)     559(48.9)     1,744(51.4)   
          Widowed, *N* (%)                                15(1.4)                                         19(1.7)       19(1.7)       53(1.6)       
          Divorced, *N* (%)                               14(1.3)                                         23(2.0)       23(2.0)       60(1.8)       
          Separated, *N* (%)                              291(26.2)                                       287(25.1)     288(25.2)     866(25.5)     
          Never married, *N* (%)                          109(9.8)                                        116(10.2)     125(10.9)     350(10.3)     
          Living with partner, *N* (%)                    30(2.7)                                         42(3.7)       58(5.1)       130(3.8)      
      Number of prescription medications taken, *N* (%)                                                                                             0.168
          \<5                                             599(89.1)                                       614(89.5)     652(86.6)     1,865(88.3)   
          \> = 5                                          73(10.9)                                        72(10.5)      101(13.4)     246(11.7)     

HDL, High-density lipoprotein; AST, aspartate aminotransferases; SD, standard deviation.

In this study, the median length of follow-up was 14.3 years. A total of 2,493 deaths (1,396 male and 1,097 female) occurred during the follow-up. The unadjusted association of the MAMC tertiles with all-cause mortality in male and female participants are shown in Figs [1](#pone.0171707.g001){ref-type="fig"} and [2](#pone.0171707.g002){ref-type="fig"}. The higher MAMC tertile had higher cumulative survival in male participants compared with the lower MAMC tertile, but this was not the case in female participants. Concerning the all-cause mortality in the male (shown in [Table 3](#pone.0171707.t003){ref-type="table"}) and female (shown in [Table 4](#pone.0171707.t004){ref-type="table"}) participants, a significant association was observed in male participants between the highest tertile of MAMC and all-cause mortality in both the univariable and multivariable adjusted analyses compared with the lowest tertile of MAMC, but this association was not observed in female participants.

![Kaplan Meier plot of association of mid-arm muscle circumference tertiles with all-cause mortality in the US male individuals.](pone.0171707.g001){#pone.0171707.g001}

![Kaplan Meier plot of association of mid-arm muscle circumference tertiles with all-cause mortality in the US female individuals.](pone.0171707.g002){#pone.0171707.g002}

10.1371/journal.pone.0171707.t003

###### Cox proportional hazards regression of all-cause mortality for mid-arm muscle circumference in the US male individuals.

![](pone.0171707.t003){#pone.0171707.t003g}

  ------------------------------------------------------------------------------------------------------------------------------
  Models [^a^](#t003fn001){ref-type="table-fn"}   Tertiles of mid-arm muscle circumference   Hazard Ratio(95%CI)    *P* -value
  ----------------------------------------------- ------------------------------------------ ---------------------- ------------
  Model 1                                         • T2 v.s. T1\                              • 0.53 (0.45--0.61)\   • \<0.001\
                                                  • T3 v.s. T1                               • 0.37 (0.31--0.44)    • \<0.001

  Model 2                                         • T2 v.s. T1\                              • 0.82(0.69--0.97)\    • 0.019\
                                                  • T3 v.s. T1                               • 0.76(0.61--0.94)     • 0.014

  Model 3                                         • T2 v.s. T1\                              • 0.82(0.69--0.97)\    • 0.022\
                                                  • T3 v.s. T1                               • 0.77(0.61--0.96)     • 0.020

  Model 4                                         • T2 v.s. T1\                              • 0.80(0.67--0.95)\    • 0.012\
                                                  • T3 v.s. T1                               • 0.75(0.60--0.94)     • 0.013

  Model 5                                         • T2 v.s. T1\                              • 0.83(0.69--0.98)\    • 0.033\
                                                  • T3 v.s. T1                               • 0.76(0.61--0.95)     • 0.018
  ------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Adjustment for age, race, sex, BMI and waist circumference.

Model 3 = Model 2 + serum total cholesterol, serum HDL, serum glucose, C-reactive protein, serum uric acid, and serum total bilirubin.

Model 4 = Model 3 + systolic blood pressure, smoking, type 2 diabetes mellitus, congestive heart failure.

Model 5 = Model 4 + (serum albumin, marital status, number of prescription medications taken).

10.1371/journal.pone.0171707.t004

###### Cox proportional hazards regression of all-cause mortality for mid-arm muscle circumference in the US female individuals.

![](pone.0171707.t004){#pone.0171707.t004g}

  ------------------------------------------------------------------------------------------------------------------------------
  Models [^a^](#t004fn001){ref-type="table-fn"}   Tertiles of mid-arm muscle circumference   Hazard Ratio(95%CI)    *P* -value
  ----------------------------------------------- ------------------------------------------ ---------------------- ------------
  Model 1                                         • T2 v.s. T1\                              • 0.78 (0.65--0.94)\   • 0.008\
                                                  • T3 v.s. T1                               • 0.88 (0.74--1.04)    • 0.125

  Model 2                                         • T2 v.s. T1\                              • 0.84(0.69--1.02)\    • 0.074\
                                                  • T3 v.s. T1                               • 0.99(0.80--1.23)     • 0.940

  Model 3                                         • T2 v.s. T1\                              • 0.80(0.66--0.98)\    • 0.027\
                                                  • T3 v.s. T1                               • 0.95(0.76--1.18)     • 0.632

  Model 4                                         • T2 v.s. T1\                              • 0.81(0.67--0.99)\    • 0.036\
                                                  • T3 v.s. T1                               • 0.92(0.74--1.14)     • 0.450

  Model 5                                         • T2 v.s. T1\                              • 0.84(0.69--1.02)\    • 0.075\
                                                  • T3 v.s. T1                               • 0.94(0.75--1.17)     • 0.583
  ------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Adjustment for age, race, sex, BMI and waist circumference.

Model 3 = Model 2 + serum total cholesterol, serum HDL, serum glucose, C-reactive protein, serum uric acid, and serum total bilirubin.

Model 4 = Model 3 + systolic blood pressure, smoking, type 2 diabetes mellitus, congestive heart failure.

Model 5 = Model 4 + (serum albumin, marital status, number of prescription medications taken).

Discussion {#sec012}
==========

In this study, we investigated a nationally representative sample of adults in the US population to determine whether there is an association between MAMC and all-cause mortality risk. The link between MAMC and all-cause mortality in US individuals has not been comprehensively evaluated. Most notably, this is the first study to demonstrate the relationship between MAMC and all-cause mortality in male and female individuals. These findings confirmed that a higher MAMC is associated with a lower risk of mortality in male individuals, with up to 24% lower risk for all-cause mortality, but there is no benefit in all-cause mortality in female individuals.

Emerging evidence has shown that MAMC is one of the main anthropometric parameters and distinguishing predictors of all-cause mortality in Asian and Western participants \[[@pone.0171707.ref002]--[@pone.0171707.ref006]\]. In a meta-analysis of prospective cohort studies of 35,287 participants, the overall mortality risk in participants with sarcopenic obesity defined by MAMC was increased by 46% (HR 1.46, 95% CI 1.23--1.73), compared with healthy participants \[[@pone.0171707.ref005]\]. Moreover, the results from the aging and longevity study in the Sirente geographic area \[[@pone.0171707.ref002]\] showed that in older adults, hazard ratios of mortality were 0.45 (95% confidence interval, 0.23--0.87), associated with the high tertile of MAMC. Previous research has also highlighted that high MAMC is a significant predictor of preserved physical performance and function, good quality of life and mental health \[[@pone.0171707.ref002],[@pone.0171707.ref004]\]. These studies tend to indicate that MAMC is a significant predictor of all-cause mortality due to its applicability for routine use based on common clinical practice, and our results significantly confirm another potential prediction of all-cause mortality in US male participants.

Plausible explanations for this positive association between MAMC and all-cause mortality risk in individuals are multifactorial, including a decline in total muscle or fat-free mass, disturbance of glucose and lipid metabolism, and decreased plasma fatty acid utilization and oxidation. First, a decline in total muscle or fat-free mass, which has been related to total mortality, may be profoundly modulated by a number of physiological factors and may contribute to a low MAMC measurement \[[@pone.0171707.ref002]--[@pone.0171707.ref006],[@pone.0171707.ref010]\]. Another previous study revealed that poorer muscle strength was associated with more difficulties in performing the physical activities of daily living \[[@pone.0171707.ref011]\]. Moreover, decreased physical activity predicted a decline in muscle strength and an increased risk of losing muscle mass \[[@pone.0171707.ref012]--[@pone.0171707.ref013]\]. The presence of an underlying medical illness (e.g., diabetes mellitus, strokes, and heart disease, including CAD) was also associated with decreased muscle mass and strength \[[@pone.0171707.ref014]\]. Proposed pathways of illness-related muscle impairment include physical inactivity, nutritional depletion, and systemic inflammation, which are risk factors associated with increased mortality rates \[[@pone.0171707.ref015]--[@pone.0171707.ref018]\]. Second, the disturbance of glucose and lipid metabolism has been found to play an important role in the association between MAMC and all-cause mortality risk. A decline in subcutaneous muscle might affect glucose and lipid metabolism, and another study has shown a relevance between intramuscular lipid and insulin resistance \[[@pone.0171707.ref019]\]. Additionally, previous research determined that higher glucose clearance and better preserved insulin sensitivity are detected in arm muscles than leg muscles, and these findings could result from differences in vascular responsiveness \[[@pone.0171707.ref020]\]. Third, reduced plasma fatty acid utilization and oxidation in the skeletal muscles of the arm have been reported in patients with obesity \[[@pone.0171707.ref021]--[@pone.0171707.ref023]\]. Patients with sarcopenic obesity, which is defined by both low muscle mass and obesity, might have an increased risk of mortality \[[@pone.0171707.ref005]\]. Recent studies extended the findings and demonstrated that impaired plasma free fatty acid utilization in forearm skeletal muscle and the activity of muscle oxidative enzymes were reduced in type 2 diabetes \[[@pone.0171707.ref021],[@pone.0171707.ref023]\]. This may facilitate increased triacylglycerol storage and adipose tissue stores within skeletal muscle, leading to obesity, insulin resistance and hyperglycemia. Upper-body subcutaneous adipose tissue, measured by neck circumference, may be positively correlated with a high cardiovascular disease risk \[[@pone.0171707.ref024]\]. These research findings probably explain why the MAMC plays an important role in the prediction of all-cause mortality in the present study. These findings expand on our existing knowledge and strengthen the importance of using anthropometric assessment tools as potential clinical predictors of individuals at risk of all-cause mortality.

The plausible explanations for the presence of gender differences in muscle size-mortality relationships are biological differences in gender, including genetic factors, hormones effects and immune system responses, muscle capacity and physical function \[[@pone.0171707.ref025]--[@pone.0171707.ref028]\]. In general, men have higher total muscle mass and greater muscle capacity than women due to hormone effects, such as much higher levels of testosterone in men. Previous studies also demonstrated that males have greater muscle strength and higher physical performance, such as higher gait speed, than females \[[@pone.0171707.ref025]--[@pone.0171707.ref028]\]. Another explanation for MAMC predicting all-cause mortality in men but not women is women's greater life expectancy, which would result in fewer deaths in women over the limited follow-up period. However, more evidence is still needed to explain the gender differences in muscle size-mortality relationships. In this study, we have explored evidence in support of the relationship between muscle size (MAMC) and all-cause mortality in male individuals. Early detection of decreased levels of MAMC may be beneficial in learning to recognize which male individuals are most in need of intervention to reduce their risk of mortality.

There were several potential limitations in this study. First, MAMC was collected at only one point during the follow-up period, which contributed to biased results. Second, self-reported medical conditions and the smoking status of individuals may on occasion have led to over-reporting and may be affected by recall bias or misclassification. Finally, despite adjustments having been made for a large number of potentially confounding factors, unmeasured confounders of the association between MAMC and the risk of all-cause mortality in US individuals cannot be ruled out.

In conclusion, the present study demonstrates that among male participants in a representative sample of the US population, a significant inverse association exists between MAMC and all-cause mortality risk. The easy, noninvasive measure of MAMC in community settings and hospitals suggests that it could be a simple, useful anthropometric tool for nutritional assessment and a clinical prognostic indicator for survival. Additional studies are warranted to further elucidate the mechanism(s) of this association.
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